Johnson & Johnson (NYSE: JNJ) surpassed analysts’ expectations on revenue and earnings for the second quarter of 2019. Shares were up by 0.77% in premarket hours on Tuesday.
Net sales declined 1.3% to $20.6 billion from the same period last year but came ahead of the forecast of $20.3 billion.
Reported net income rose over 41% to $5.6 billion, or $2.08 per share, compared to the year-ago period. Adjusted earnings rose 22% to $6.9 billion, or $2.58 per share, beating estimates of $2.43 per share.
On a reported basis, sales declined 2.2% in the US and 0.3% internationally versus last year. On an adjusted operational basis, US sales reflected no change while international sales rose 7.6%.
During the quarter, sales rose 1.2% in the Consumer segment and 1.7% in the Pharmaceuticals segment on a reported basis while in the Medical Devices unit, sales declined 6.9%. On an adjusted operational basis, all three divisions recorded sales increases.
Adjusted operational sales in the Consumer division grew 2.3%, driven by NEUTROGENA, AVEENO and OGX beauty products as well as OTC products. Sales in Pharmaceuticals rose 4.4%, helped by products like DARZALEX, STELARA and IMBRUVICA. In Medical Devices, sales increased 3.2%, driven by growth in electrophysiology products, endocutters and international energy products.
For the full year of 2019, J&J raised its reported sales guidance to a range of $80.8 billion to $81.6 billion versus the previous outlook of $80.4 billion to $81.2 billion. Adjusted EPS is expected to be $8.53-8.63.
Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a
PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the
With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,